home / stock / ymab / ymab message board
Subject | By | Source | When |
---|---|---|---|
$YMAB: WHAT????? | Invest-in-America | investorshub | 04/02/2023 2:50:17 PM |
there she goes | TrendTrade2016 | investorshub | 03/31/2023 2:34:59 PM |
HERE COMES THE 5 DOLLA BREAK | TrendTrade2016 | investorshub | 03/31/2023 2:28:43 PM |
$YMAB TO 5.34 | TrendTrade2016 | investorshub | 03/31/2023 2:21:26 PM |
YMAB...ANOTHER BIO READY TO FLY | TrendTrade2016 | investorshub | 03/31/2023 2:07:20 PM |
Looks like the train is leaving the station. | weatherfuel | investorshub | 11/02/2022 3:38:44 PM |
Yes it does | INFINITI | investorshub | 10/31/2022 6:48:15 PM |
Looking like a good bounce play setting up. | weatherfuel | investorshub | 10/31/2022 3:52:49 PM |
On the move. | KeepOn | investorshub | 02/13/2022 3:24:00 AM |
TUTES ADDING : including pension plans, Ivy | crudeoil24 | investorshub | 02/11/2022 3:56:18 PM |
HEADING BACK TO $50.00+ > the 52 wk. | crudeoil24 | investorshub | 02/11/2022 3:52:25 PM |
Y-mAbs Announces Completion of Pre-BLA Meeting with FDA | crudeoil24 | investorshub | 02/11/2022 3:39:39 PM |
Y-mAbs Announces Sale of Priority Review Voucher | Phosphene | investorshub | 12/31/2020 1:42:37 PM |
8-K: License agreement with SciClone Pharmaceuticals International. | Phosphene | investorshub | 12/24/2020 2:16:10 AM |
Y-mAbs Announces Pipeline Update | Phosphene | investorshub | 12/17/2020 11:57:56 AM |
SEC Form 4. Director Thomas Gad | Phosphene | investorshub | 12/15/2020 4:01:28 PM |
8K today. Y-mAbs Announces Update on DANYELZA | Phosphene | investorshub | 12/09/2020 11:11:35 PM |
FDA Approves Y-mAbs DANYELZA (naxitamab-gqgk) for the Treatment | Phosphene | investorshub | 12/09/2020 4:16:21 AM |
Y-mAbs to Host Virtual Research & Development Day | Phosphene | investorshub | 12/09/2020 4:15:30 AM |
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmace...
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmace...
NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmace...